De Boer Rob J, Perelson Alan S
Theoretical Biology and Bioinformatics, Utrecht University, Utrecht, The Netherlands
Santa Fe Institute, Santa Fe, New Mexico, USA.
J Virol. 2017 Oct 27;91(22). doi: 10.1128/JVI.00983-17. Print 2017 Nov 15.
Many HIV-1-infected patients evolve broadly neutralizing antibodies (bnAbs). This evolutionary process typically takes several years and is poorly understood as selection taking place in germinal centers occurs on the basis of antibody affinity. B cells with the highest-affinity receptors tend to acquire the most antigen from the follicular dendritic cell (FDC) network and present the highest density of cognate peptides to follicular helper T (Tfh) cells, which provide survival signals to the B cell. bnAbs are therefore expected to evolve only when the B cell lineage evolving breadth is consistently capturing and presenting more peptides to Tfh cells than other lineages of more specific B cells. Here we develop mathematical models of Tfh cells in germinal centers to explicitly define the mechanisms of selection in this complex evolutionary process. Our results suggest that broadly reactive B cells presenting a high density of peptides bound to major histocompatibility complex class II molecules (pMHC) are readily outcompeted by B cells responding to lineages of HIV-1 that transiently dominate the within host viral population. Conversely, if broadly reactive B cells acquire a large variety of several HIV-1 proteins from the FDC network and present a high diversity of several pMHC, they can be rescued by a large fraction of the Tfh cell repertoire in the germinal center. Under such circumstances the evolution of bnAbs is much more consistent. Increasing either the magnitude of the Tfh cell response or the breadth of the Tfh cell repertoire markedly facilitates the evolution of bnAbs. Because both the magnitude and breadth can be increased by vaccination with several HIV-1 proteins, this calls for experimental testing. Many HIV-infected patients slowly evolve antibodies that can neutralize a large variety of viruses. Such broadly neutralizing antibodies (bnAbs) could in the future become therapeutic agents. bnAbs appear very late, and patients are typically not protected by them. At the moment, we fail to understand why this takes so long and how the immune system selects for broadly neutralizing capacity. Typically, antibodies are selected based on affinity and not on breadth. We developed mathematical models to study two different mechanisms by which the immune system can select for broadly neutralizing capacity. One of these is based upon the repertoire of different follicular helper T (Tfh) cells in germinal centers. We suggest that broadly reactive B cells may interact with a larger fraction of this repertoire and demonstrate that this would select for bnAbs. Intriguingly, this suggests that broadening the Tfh cell repertoire by vaccination may speed up the evolution of bnAbs.
许多感染HIV-1的患者会产生广泛中和抗体(bnAbs)。这一进化过程通常需要数年时间,而且由于生发中心发生的选择是基于抗体亲和力,所以人们对此了解甚少。具有最高亲和力受体的B细胞往往能从滤泡树突状细胞(FDC)网络获取最多的抗原,并向滤泡辅助性T(Tfh)细胞呈递同源肽的密度最高,而Tfh细胞会为B细胞提供存活信号。因此,只有当进化出广度的B细胞谱系持续捕获并向Tfh细胞呈递比其他更具特异性的B细胞谱系更多的肽时,才有望进化出bnAbs。在此,我们建立了生发中心Tfh细胞的数学模型,以明确界定这一复杂进化过程中的选择机制。我们的结果表明,呈递高密度与主要组织相容性复合体II类分子结合的肽(pMHC)的广泛反应性B细胞很容易被对在宿主病毒群体中短暂占主导地位的HIV-1谱系作出反应的B细胞所淘汰。相反,如果广泛反应性B细胞从FDC网络获取多种HIV-1蛋白并呈递多种pMHC的高度多样性,它们就可以被生发中心中很大一部分Tfh细胞库拯救。在这种情况下,bnAbs的进化会更加一致。增加Tfh细胞反应的强度或Tfh细胞库的广度都能显著促进bnAbs的进化。由于通过接种多种HIV-1蛋白可以同时增加强度和广度,这就需要进行实验测试。许多HIV感染患者会缓慢产生能够中和多种病毒的抗体。这种广泛中和抗体(bnAbs)未来可能会成为治疗药物。bnAbs出现得非常晚,而且患者通常无法受到它们的保护。目前,我们不明白为什么这需要这么长时间,以及免疫系统是如何选择出广泛中和能力的。通常,抗体是基于亲和力而非广度来选择的。我们开发了数学模型来研究免疫系统选择广泛中和能力的两种不同机制。其中一种基于生发中心不同滤泡辅助性T(Tfh)细胞的库。我们认为广泛反应性B细胞可能会与这个库中的更大一部分相互作用,并证明这将选择出bnAbs。有趣的是,这表明通过接种疫苗拓宽Tfh细胞库可能会加速bnAbs的进化。